Agents for Accelerated Clinical Trial Design
Company is active
Event Year: 2025
Company is active
Event Year: 2025
Delineate is developing AI-powered agents designed to accelerate and enhance the clinical trial design process. Operating within a substantial $10 billion market, the company focuses on optimizing trial efficiency, where even a single day's reduction in timeline can translate to a $1-5 million revenue impact. Delineate streamlines research by converting existing clinical trial data into specialized, readily accessible datasets, saving scientists significant time and resources. Currently, Delineate collaborates with major pharmaceutical corporations, assisting them in expediting their progress to subsequent trial phases by constructing comprehensive datasets on specific drug classes.
Delineate is developing AI-powered agents designed to accelerate and enhance the clinical trial design process. Operating within a substantial $10 billion market, the company focuses on optimizing trial efficiency, where even a single day's reduction in timeline can translate to a $1-5 million revenue impact. Delineate streamlines research by converting existing clinical trial data into specialized, readily accessible datasets, saving scientists significant time and resources. Currently, Delineate collaborates with major pharmaceutical corporations, assisting them in expediting their progress to subsequent trial phases by constructing comprehensive datasets on specific drug classes.
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2025
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2025
B2B
B2B
B2B -> Engineering, Product and Design
B2B -> Engineering, Product and Design
Team size: 20
Hiring: No
Team size: 20
Hiring: No
